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Introduction {#cam4865-sec-0001}
============

The issue of classification of primary cutaneous B‐cell lymphomas (PCBCL) other than marginal zone lymphoma (MZL) has been matter of debate. The 2008 WHO Lymphoma Classification [1](#cam4865-bib-0001){ref-type="ref"} recognizes two subtypes: primary cutaneous follicular center cell lymphoma (PCFCCL) and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT). PCFCCL is defined on the basis of cytological features (presence of centrocytes) irrespective of growth pattern, which may be variable from follicular to predominantly diffuse; in some case, mostly advanced tumors, the lymphoma infiltrate may contain a prevalence of large cells, a feature which seems not to affect prognosis. PCDLBCL‐LT designs all cutaneous B‐cell lymphomas with a diffuse pattern and composed of monotonous proliferation of centroblasts and immunoblasts, usually BCL2‐positive, irrespective of site of presentation. This two‐tiered distinction was validated by clinical studies [2](#cam4865-bib-0002){ref-type="ref"}, [3](#cam4865-bib-0003){ref-type="ref"} and was partially supported by the identification of different molecular signatures and imbalances [4](#cam4865-bib-0004){ref-type="ref"} in PCFCCL and PCDLBCL‐LT, the latter resembling the activated B‐cell type (ABC) of nodal DLBCL [5](#cam4865-bib-0005){ref-type="ref"}, [6](#cam4865-bib-0006){ref-type="ref"}.

In the previous WHO/EORTC classification (2005) [7](#cam4865-bib-0007){ref-type="ref"}, [8](#cam4865-bib-0008){ref-type="ref"}, the heading of cutaneous diffuse large B‐cell lymphomas comprised several variants, including PCDLBCL‐LT, cases with peculiar morphology (T‐cell/histiocyte rich, plasmablastic) as well as diffuse lymphomas of centroblastic‐like cells, intermingled with a mixed inflammatory infiltrate and with variable expression of BCL2, which are named primary cutaneous diffuse large B‐cell lymphoma, other (PCDLBCL‐O). PCDLBCL‐O basically represents a morphological variant lacking the typical features of PCDLBCL‐LT neither conforming to the definition of PCFCCL, whereas on the clinical ground, its behavior seems at least to partially overlap the indolent course of PCFCCL. In fact, the present WHO lymphoma classification overcame the previous WHO/EORTC and included at least a part of PCDLBCL‐O within the spectrum of PCFCCL.

In spite of the advances in the classification, the identification of this putative variant remains not trivial, since it might harbor significant prognostic and therapeutic implications. While the 5‐year disease‐specific survival in PCDLBCL‐LT is 41%, PCFCCL carries an excellent prognosis, with a 95% 5‐year survival [1](#cam4865-bib-0001){ref-type="ref"} even in cases featuring a predominance of large cells, which may benefit from a conservative therapeutic approach. Since only few studies focused on such issue and indeed no conclusive data are available on large series [9](#cam4865-bib-0009){ref-type="ref"}, [10](#cam4865-bib-0010){ref-type="ref"}, question still remains whether such group of PCBCL with borderline features between PCFCCL and PCDLBCL‐LT could define a further distinct category.

To clarify the existence of an additional clinicopathologic subset of PCLBCL, we retrospectively analyzed a large multicentric series of PCBCL other than MZL and tested the prognostic relevance of several factors, including cytomorphologic features, histogenetic profiles, and BCL2 status [11](#cam4865-bib-0011){ref-type="ref"}.

Methods {#cam4865-sec-0002}
=======

Selection of patients {#cam4865-sec-0003}
---------------------

This multicentric study retrospectively analyzed the clinicopathologic features of a series of 197 PCBCL other than MZL, diagnosed between 1993 and 2010 at 10 centers referring to the "Gruppo Italiano di studio dei Linfomi Cutanei (G.I.L.C.)" of the "Fondazione Italiana Linfomi (F.I.L.)." Approval for this study was obtained from the local institutional ethical committee. Data management was made according to the Helsinki Declaration of 1975, revised in 1983 and 2000.

Inclusion criteria were as follows: (1) primary cutaneous disease, documented through comprehensive staging, and no extracutaneous spread for at least 6 months after diagnosis; (2) availability of representative formalin‐fixed, paraffin‐embedded (FFPE) lesional blocks; and (3) clinical follow‐up. A particular focus was addressed to cases featuring a predominance of large cells, encompassing the whole spectrum of PCDLBCL according to both WHO and WHO/EORTC classifications. Thirty‐six cases were excluded because of a history of systemic lymphoma or limited follow‐up.

Histological review {#cam4865-sec-0004}
-------------------

### Immunohistochemistry {#cam4865-sec-0005}

For all cases, histochemical and immunohistochemical staining was reviewed by a panel of six expert pathologists (M. P., E. B., C. T., S. A., M. G., and M. S.). Automated immunostainings were performed on FFPE slides through streptavidin‐biotin‐peroxidase‐conjugated (SABC) method after antigen retrieval procedures, when needed. Tested antibodies included CD20, CD79a, BCL2, CD10, BCL6, MUM1, MYC, HGAL, CD138, CD3, CD5, Mib1/Ki‐67, CD21, CD23, CD30, BCL1, and ALK/p80. BCL2, BCL6, and CD10 immunostainings were considered positive if \>50% of the cells were stained. MUM1 positivity was assessed upon a cutoff value of 30%. MiB1/Ki67 expression was assigned to a low (\<50%) or high proliferative (\>50%) index. Histogenesis was defined according to Hans algorithm [12](#cam4865-bib-0012){ref-type="ref"}, and thus a "germinal center B‐cell" (GC) or a "non‐germinal center B‐cell" (non‐GC) profile was assigned. The so‐called double hit score (DHS) was assigned to DLBCL based on a cutoff value of 75% for BCL2 positivity and of 40% for MYC positivity [13](#cam4865-bib-0013){ref-type="ref"}.

Diagnoses were primarily based on the 2008 WHO classification criteria [1](#cam4865-bib-0001){ref-type="ref"}. When a disagreement occurred, final diagnosis was obtained by consensus. Lesional architecture was identified as nodular, nodular/diffuse, or diffuse; the presence of residual dendritic meshwork was noted. Cytologic features were defined primarily on nuclear morphology either as small‐to‐large centrocytes (cleaved cells) or as centroblasts and immunoblasts (nucleolated, noncleaved cells).

Cases with a predominance of small‐to‐large centrocytes and a minority of centroblasts/immunoblasts were classified as PCFCCL, independently from growth pattern (Fig. S1). Proliferations showing a diffuse pattern and mostly consisting of centroblasts/immunoblasts with only few small, centrocytoid lymphocytes were named PCDLBCL‐LT (Fig. [1](#cam4865-fig-0001){ref-type="fig"}).

![The typical picture of PCDLBCL‐LT is represented, as tumoral lesions arising on the lower limbs (A), composed of a proliferation of large, round cells with centroblastic and/or immunoblastic features (B; Giemsa stain, 400×) and frequent coexpression of BCL2 and MYC (C and D; SABC method, 400×). PCDLBCL‐LT, primary cutaneous diffuse large B‐cell lymphoma, leg type; BCL2, B‐cell lymphoma; SABC, streptavidin‐biotin‐peroxidase‐conjugated.](CAM4-5-2740-g001){#cam4865-fig-0001}

Cases almost entirely composed of large cells (centroblasts), though with a mixed inflammatory background and/or a minority (\<10%) of large centrocytoid cells, and with a predominantly diffuse pattern were observed (Fig. [2](#cam4865-fig-0002){ref-type="fig"}). These tumors lacked the typical features both of PCDLBCL‐LT and PCFCCL, and thus they were named PCDLBCL, not otherwise specified (PCDLBCL‐NOS).

![This case of PCDLBCL‐NOS arose as a tumoral lesion on the neck (A); histologic picture is consistent with a nodular to diffuse proliferation (B, hematoxylin--eosin, 100×) of predominantly large, centroblastic cells (C, Giemsa stain 400×) with a mixed inflammatory infiltrate (D, hematoxylin--eosin 400×). Picture (C) is representative of a PCDLBCL‐NOS‐non‐GC cases, which resulted MUM1‐positive (E, SABC method, 400×), whereas CD10 stain (F, SABC method, 400×) corresponds to the PCDLBCL‐NOS‐GC cases shown in picture (D). BCL2 is usually negative (G, SABC method, 400×), whereas the small, intermixed lymphocytes usually display a T‐cell, CD3+ phenotype (H, SABC method, 400×). PCDLBCL‐NOS‐non‐GC, primary cutaneous diffuse large B‐cell lymphoma, not otherwise specified non‐germinal center B‐cell; SABC, streptavidin‐biotin‐peroxidase‐conjugated.](CAM4-5-2740-g002){#cam4865-fig-0002}

Molecular biology {#cam4865-sec-0006}
-----------------

Interphasic fluorescence in situ hybridization (FISH) analysis for *BCL*2 translocation was performed on routine paraffin sections (3--4 *μ*m) using an *IGH/BCL2* Dual Color, Dual Fusion Translocation Probe (Vysis Abbott, Des Plaines, IL, USA). This probe is a mixture of the *IGH* probe, labeled with SpectrumGreen and spanning \~1.5 Mb, thus containing sequences homologous to the entire *IGH* locus as well as sequences extending about 300 kb beyond the 3′‐end of the *IGH* locus, and the *BCL2* probe, labeled with SpectrumOrange and covering gene, covering an approximate 750‐kb region. The expected pattern in a normal nucleus hybridized is the two orange, two green; if harboring a t(14;18), the most common pattern is one orange signal, one green signal, and two orange/green (yellow) fusion signals, representing the two derivative chromosomes resulting from the reciprocal translocation. The evaluation was carried out using direct viewing on a standard fluorescence microscope, and the images were elaborated with Powergene Macprobe v.4.4 software (Applied Imaging, Newcastle‐upon‐Tyne, UK). In each case, more than 100 nuclei on paraffin‐embedded sections were examined; if more than 15% of nuclei displayed the translocation, we considered the case as positive.

Epstein‐Barr virus (EBV) status was tested by in situ hybridization (ISH) using a fluorescein isothiocyanate‐labeled peptic nucleic acid (PNA) probe, complementary to the EBV‐encoded RNAs (*EBER*s) (DakoCytomation, Glostrup, Denmark).

Statistical analysis {#cam4865-sec-0007}
--------------------

Data were described as mean and standard deviation if continuous variable and counts and percent if categorical variable and compared between diagnostic groups with the one‐way analysis of variance and the Fisher exact test, respectively. Survival and event‐free survival were described with Kaplan--Meier method. Predictors were identified with the log‐rank test, and the Cox model was used to compute the corresponding hazard ratios and their 95% confidence intervals (HR, 95% CI). The analysis was performed on the entire case series and on predefined meaningful subgroups. The median follow‐up (25th--75th percentiles) was computed according to the inverse Kaplan--Meier method.

Stata13 (StataCorp, College Station, TX) was used for computation. A two‐sided *P*‐value was considered statistically significant. For post hoc comparisons, the Bonferroni correction was applied.

Results {#cam4865-sec-0008}
=======

Histological classification {#cam4865-sec-0009}
---------------------------

According to the panel approach, 96/161 cases (59%) were classified as PCFCCL, 40/161 (25%) as PCDLBCL‐NOS, and 25/161 (16%) as PCDLBCL‐LT.

Briefly, in PCFCCL (Fig. S1), the infiltrate mainly consisted of small‐ to medium‐sized centrocytes, with a variable amount of centroblasts, whereas large cells (both centrocytes and centroblasts) were predominant in 20/96 (21%) cases. A spindle cell morphology was observed in 11 cases. Growth pattern was nodular in 33/96 (34%) cases, nodular and diffuse in 39/96 (41%), and purely diffuse in 24/96 (25%), whereas remnants of follicular dendritic meshwork were usually observed. A reactive lymphocytic and histiocytic background was always present, at times so abundant to obscure the lymphoma B cells.

In PCDLBCL‐NOS (Fig. [2](#cam4865-fig-0002){ref-type="fig"}), the infiltrate showed a purely diffuse growth pattern in 25/40 (63%) cases, while limited gross nodular areas were observed in 15/25 (37%) cases; in 11/40 (27%) cases, a residual dendritic meshwork was noted, though very focal and with features of disruption. Tumor cells were chiefly centroblasts and were usually intermingled with a variable reactive cellular background, mostly composed of small reactive CD3+ lymphocytes.

PCDLBCL‐LT (Fig. [1](#cam4865-fig-0001){ref-type="fig"}) was composed exclusively of large round nucleolated cells, with predominance of immunoblasts, growing in a diffuse pattern with common effacement of adnexa, focal necrosis with sparse nuclear debris, and a very scanty, if present, inflammatory background nor stromal reaction; no dendritic meshwork was detected.

Although within a wide range, median proliferative index was generally low in PCFCCL (30%, range 10--90%) and high in PCDLBCL‐LT (70%, range 50--90%), whereas an intermediate value was documented in PCDLBCL‐NOS (50%, range 10--90%).

All PCFCCLs were positive for either CD10 or Bcl6 and negative for MUM1, whereas PCDLBCL subtypes were split in the two histogenetic groups. For PCDLBCL‐NOS, 26/40 (65%) cases were recorded as GC and 14/40 (35%) as non‐GC; among PCDLBCL‐LT, 5/25 (20%) cases fell into GC and 20/25 (80%) into non‐GC subgroup. MYC positivity was documented in 10 of 21 (48%) tested cases of PCDLBCL‐NOS and in 11/13 (85%) PCDLBCL‐LT, whereas it turned out to be negative in PCFCCL. As to DHS, cases were stratified into a two‐tiered system (0--1 vs. 2): within PCDLBCL‐NOS, 16/24 cases scored DHS = 0--1 and 8/24 DHS = 2; among PCDLBCL‐LT, 18 cases 5/18 cases scored DHS = 0--1 and 13/18 DHS = 2. Comprehensive histopathologic and phenotypic features are detailed in Table [1](#cam4865-tbl-0001){ref-type="table-wrap"}.

###### 

Histologic features

  Histopathologic features             PCFCCL                                                      PCDLBCL‐NOS                                                                  PCDLBCL‐LT                                                                    *P*
  ------------------------------------ ----------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------- ------------------
  Cytology                             Prevalence of small to large, cleaved cells (centrocytes)   Prevalence of round, nucleolated cells (centroblasts, rarely immunoblasts)   Almost exclusively round, nucleolated cells (centroblasts and immunoblasts)   ---
  Reactive T cells                     Present                                                     Present                                                                      Very scanty                                                                   ---
  Growth pattern (%)                   Nodular to diffuse                                          Typically diffuse                                                            Diffuse                                                                       NA
  Nodular                              33/96 (34)                                                  0/40 (0)                                                                     0/25 (0)                                                                      
  Nodular/diffuse                      39/96 (41)                                                  15/40 (38)                                                                   0/25 (0)                                                                      
  Diffuse                              24/96 (25)                                                  25/40 (62)                                                                   25/25 (100)                                                                   
  Dendritic meshwork, present (%)      80/96 (83)                                                  11/40 (27)[a](#cam4865-note-0003){ref-type="fn"}                             1/25 (4)[a](#cam4865-note-0003){ref-type="fn"}                                \<0.001
  Infiltrate extension (%)                                                                                                                                                                                                                                    \<0.001
  Dermic                               44/96 (46)                                                  22/40 (55)                                                                   0/25 (0)                                                                      
  Dermic/hypodermic                    52/96 (54)                                                  18/40 (45)                                                                   25/25 (100)                                                                   
  Skin ulceration (%)                  0/96 (0)                                                    4/40 (10)                                                                    4/25 (16)                                                                     NA
  Adnexal effacement, present (%)      3/96 (3)                                                    6/40 (15)                                                                    10/25 (40)                                                                    NA
  Necrosis                             0/96 (0)                                                    2/40 (5)                                                                     4/25 (16)                                                                     NA
  Nuclear debris                       0/96 (0)                                                    4/40 (10)                                                                    15/25 (60)                                                                    NA
  Starry sky appearance                0/96 (0)                                                    0/40 (0)                                                                     11/25 (44)                                                                    NA
  BCL2, +/total (%)                    29/96 (30)                                                  16/40 (40)                                                                   19/25 (76)                                                                    \<0.001
  CD10, +/total (%)                    57/96 (59)                                                  11/40 (27)                                                                   0/25 (0)                                                                      \<0.001
  BCL6, +/total (%)                    84/96 (87)                                                  33/40 (82)                                                                   14/25 (56)                                                                    0.001
  MUM1, +/total (%)                    0/96 (0)                                                    14/40 (40)                                                                   20/25 (80)                                                                    0.004
  HGAL, +/total (%)                    50/54 (93)                                                  9/40 (22)                                                                    1/25 (4)                                                                      \<0.001
  MYC, +/total (%)                     0/40 (0)                                                    10/21 (48)                                                                   11/13 (85)                                                                    \<0.001
  Ki67 median % (range)                30 (10--90)                                                 50 (10--90)                                                                  70 (50--90)                                                                   ---
  Histogenetic profile, GC/total (%)   96/96 (100)                                                 26/40 (65)                                                                   5/25 (20)                                                                     \<0.001
  DHS (%)                                                                                                                                                                                                                                                     All: \<0.001
  0--1                                 NA                                                          16/24                                                                        5/18                                                                          NOS vs. LT: 0.28
  2                                    NA                                                          8/24                                                                         13/18                                                                         
  *BCL2* translocation +/total (%)     15/75 (20)                                                  3/27 (11)                                                                    1/20 (5)                                                                      0.234
  BCL2 status (p)                      (\<0.001)                                                   (0.273)                                                                      \(1\)                                                                         ---
  FISH+/IHC+ (%)                       11/23 (48)                                                  3/17 (17)                                                                    1/17 (6)                                                                      
  FISH+/IHC− (%)                       4/52 (8)                                                    0/10 (0)                                                                     0/3 (0)                                                                       
  EBV, +/total (%)                     NA                                                          0/15 (0)                                                                     0/20 (0)                                                                      NA

PCFCCL, primary cutaneous follicular center cell lymphoma; PCDLBCL‐NOS, primary cutaneous diffuse large B‐cell lymphoma, not otherwise specified; PCDLBCL‐LT, primary cutaneous diffuse large B‐cell lymphoma, leg type; GC, germinal center (Hans algorithm); DHS, double‐hit score; NA, not assessed (group too small for statistical analysis); FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.

Only very focal and disrupted, if present.

John Wiley & Sons, Ltd

Molecular biology {#cam4865-sec-0010}
-----------------

FISH analysis for *BCL2* translocation was performed in 122/161 (76%) cases (Table [1](#cam4865-tbl-0001){ref-type="table-wrap"}) and detected in 15/75 (20%) PCFCCL, in 3/27 (11%) PCDLBCL‐NOS, and in 1/20 (5%) PCDLBCL‐LT. EBV was tested in 30 PCDLBCL and resulted uniformly negative (Fig. S2).

Clinical presentation, therapy, and follow‐up {#cam4865-sec-0011}
---------------------------------------------

Clinical features, therapy, and follow‐up are summarized according to the panel diagnosis and detailed in Table [2](#cam4865-tbl-0002){ref-type="table-wrap"}. Among the three groups, a slight male‐to‐female prevalence was noticed; for PCDLBCL‐LT, a tendency toward an older age of onset was highlighted. The number of lesions (single vs. multiple) was balanced among the subgroups, whereas PCFCCL and PCDLBCL‐NOS showed a predilection for trunk and head and neck location, in contrast to PCDLBCL‐LT which involved preferentially the lower limbs.

###### 

Clinical features

  Clinical presentation                    PCFCCL         PCDLBCL‐NOS    PCDLBCL‐LT (%)   *P*
  ---------------------------------------- -------------- -------------- ---------------- ---------
  Male/female (ratio)                      53/43 (1.23)   27/13 (2.08)   17/8 (2.12)      0.432
  Mean age (range)                         54 (27--86)    63 (26--90)    76 (54--92)      \<0.001
  Number of lesions (%)                                                                   
  Single lesion                            67/96 (70)     27/40 (68)     18/25 (72)       0.889
  Multiple lesions                         29/96 (30)     13/40 (32)     6/25 (24)        
  Diffuse                                  0/96 (0)       0/40 (0)       1/25 (4)         
  Site involved (%)                                                                       
  Head and neck                            38/96 (40)     7/40 (17)      0/25 (0)         \<0.001
  Trunk                                    47/96 (49)     20/40 (50)     3/25 (12)        0.002
  Upper limbs                              8/96 (8)       8/40 (20)      1/25 (4)         NA
  Lower limbs                              7/96 (7)       9/40 (22)      21/25 (84)       \<0.001
  Type of lesion (%)                                                                      
  Nodule/tumor                             64/96 (67)     27/40 (67)     18/25 (72)       0.878
  Plaque                                   17/96 (18)     10/40 (25)     5/25 (20)        0.625
  Patch                                    4/96 (4)       1/40 (3)       2/25 (8)         NA
  Papule                                   5/96 (5)       0/40 (0)       0/25 (0)         NA
  Variable                                 6/96 (6)       2/40 (5)       0/25 (0)         NA
  Therapy and follow‐up                                                                   
  First‐line therapy                                                                      
  Surgical only                            20/96 (21)     2/40 (5)       0/25 (0)         0.004
  Radiotherapy                             47/96 (49)     15/40 (37)     9/25 (36)        \<0.001
  Chemotherapy (±radio)                    26/96 (27)     22/40 (55)     15/25 (60)       0.006
  Wait and see                             3/96 (3)       1/40 (3)       1/25 (4)         NA
  Response to therapy (%)                                                                 
  CR                                       81/96 (84)     32/40 (80)     13/25 (52)       0.002
  PR                                       15/96 (16)     8/40 (20)      12/25 (48)       
  Relapse, /CR (%)                         35/81 (43)     13/32 (41)     11/13 (85)       0.015
  Extracutaneous relapse, /CR (%)          5/81 (6)       2/32 (6)       1/25 (4)         
  Median time to relapse, months (range)   24 (6--156)    26 (5--159)    11 (5--28)       0.156
  Follow‐up                                                                               
  ADF                                      76/96 (79)     25/40 (62)     4/25 (16)        \<0.001
  AWD                                      15/96 (16)     10/40 (25)     8/25 (32)        0.140
  DOD                                      2/96 (2)       4/40 (10)      11/25 (44)       NA
  DUC                                      3/96 (3)       1/40 (3)       2/25 (8)         NA
  Median follow‐up, months (range)         47 (12--237)   53 (8--210)    19 (6--126)      0.007

PCFCCL, primary cutaneous follicular center cell lymphoma; PCDLBCL‐NOS, primary cutaneous diffuse large B‐cell lymphoma, not otherwise specified; PCDLBCL‐LT, primary cutaneous diffuse large B‐cell lymphoma, leg type; CR, complete response; PR, partial response; ADF, alive disease‐free; AWD, alive with disease; DOD, died of disease; DUC, died of unrelated cause; NA, not assessed (group too small for statistical analysis).
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Overall survival {#cam4865-sec-0012}
----------------

On the whole series, the median follow‐up was 48 months (25th--75th, 21--98). Median overall survival (OS) was not reached for any subgroup. According to the panel diagnosis (Fig. [3](#cam4865-fig-0003){ref-type="fig"}, Table [3](#cam4865-tbl-0003){ref-type="table-wrap"}), OS was significantly different between the three subgroups (*P* \< 0.001). Post hoc comparisons scored a significantly different OS for PCFCCL versus PCDLBCL‐LT (HR = 0.03, *P* \< 0.001) and for PCDLBCL‐NOS versus PCDLBCL‐LT (HR = 0.13, *P* = 0.001); however, the comparison of PCFCCL versus PCDLBCL‐NOS did not reach statistical significance (HR = 0.21, *P* = 0.073). When splitting PCDLBCL‐NOS in two histogenetic subgroups, post hoc comparisons showed a difference in OS for PCDLBCL‐NOS‐GC versus PCDLBCL‐NOS‐non‐GC, although not significant (HR = 0.15, *P* = 0.102). The difference in OS of PCDLBCL‐NOS‐GC was significant versus PCDLBCL‐LT (HR = 0.05, *P* = 0.003) but not versus PCFCCL (HR = 0.58, *P* = 0.695). For PCDLBCL‐NOS‐non‐GC, the comparison did not reach statistical significance versus PCDLBCL‐LT (HR = 0.30, *P* = 0.070) but versus PCFCCL (HR = 0.09, *P* = 0.008).

![OS curves: analysis is performed comparing the three morphologic diagnosis, according to (A), the four groups obtained when splitting PCDLBCL‐NOS according to histogenesis (B) and the three categories identified upon aggregation of PCFCCL and PCDLBCL‐NOS‐GC in a "germinal center" group (C); in the same way, EFS curves are reported (D--F). OS, overall survival; PCDLBCL‐NOS‐GC, primary cutaneous diffuse large B‐cell lymphoma, not otherwise specified germinal center B‐cell; PCFCCL, primary cutaneous follicular center cell lymphoma; EFS, event‐free survival.](CAM4-5-2740-g003){#cam4865-fig-0003}

###### 

OS and EFS according to the diagnosis and paired comparisons

                                                      2‐year OS %   5‐year OS %   *P*                                            Paired comparisons                      HR                  *P*
  --------------------------------------------------- ------------- ------------- ---------------------------------------------- --------------------------------------- ------------------- ---------
  Analysis of OS by panel diagnosis                                                                                                                                                          
  PCFCCL                                              100           98.25         \<0.001                                        PCFCCL vs. PCDLBCL‐LT                   0.03 (0.01--0.12)   \<0.001
  PCDLBCL‐NOS                                         93.98         93.98         PCDLBCL‐NOS vs. PCDLBCL‐LT                     0.13 (0.04--0.41)                       0.001               
  PCDLBCL‐LT                                          58.96         52.41         PCFCCL vs. PCDLBCL‐NOS                         0.21 (0.04--1.16)                       0.073               
  Analysis of OS by panel diagnosis + histogenesis                                                                                                                                           
  PCFCCL                                              100           95.96         \<0.001                                        PCFCCL vs. PCDLBCL‐LT                   0.03 (0.01--0.12)   \<0.001
  PCDLBCL‐NOS‐GC                                      95.45         95.45         PCFCCL vs. PCDLBCL‐NOS‐GC                      0.58 (0.05--6.42)                       0.695               
  PCDLBCL‐NOS‐non‐GC                                  91.67         91.67         PCFCCL vs. PCDLBCL‐NOS‐non‐GC                  0.09 (0.01--0.53)                       0.008               
  PCFLBCL‐LT                                          58.96         52.41         PCDLBCL‐NOS‐GC vs. PCDLBCL‐LT                  0.05 (0.01--0.36)                       0.003               
                                                                                                                                 PCDLBCL‐NOS‐non‐GC vs. PCDLBCL‐LT       0.30 (0.08--1.11)   0.070
                                                                                                                                 PCDLBCL‐NOS‐GC vs. PCDLBCL‐NOS‐non‐GC   0.15 (0.02--1.45)   0.102
  Analysis of OS by combined groups                                                                                                                                                          
  PCFCCL+PCDLBCL‐NOS‐GC                               98.95         95.90         \<0.001                                        PCFCCL+PCDLBCL‐NOS‐GC vs. PCDLBCL‐LT    0.03 (0.01--0.11)   \<0.001
  PCDLBCL‐NOS‐non‐GC                                  91.96         91.96         PCDLBCL‐NOS‐non‐GC vs. PCFLBCL‐LT              0.30 (0.08--1.11)                       0.070               
  PCDLBCL‐LT                                          58.96         52.41         PCFCCL+PCDLBCL‐NOS‐GC vs. PCDLBCL‐NOS‐non‐GC   0.10 (0.02--0.51)                       0.005               
  Analysis of EFS by panel diagnosis                                                                                                                                                         
  PCFCCL                                              75.29         51.67         \<0.001                                        PCFCCL vs. PCDLBCL‐LT                   0.21 (0.12--0.37)   \<0.001
  PCDLBCL‐NOS                                         65.69         40.30         PCDLBCL‐NOS vs. PCDLBCL‐LT                     0.24 (0.13--0.47)                       \<0.001             
  PCDLBCL‐LT                                          22.69         11.34         PCFCCL vs. PCDLBCL‐NOS                         0.86 (0.50--1.47)                       0.582               
  Analysis of EFS by panel diagnosis + histogenesis                                                                                                                                          
  PCFCCL                                              75.29         51.67         \<0.001                                        PCFCCL vs. PCDLBCL‐LT                   0.21 (0.12--0.37)   \<0.001
  PCDLBCL‐NOS‐GC                                      70.69         48.95         PCFCCL vs. PCDLBCL‐NOS‐GC                      1.08 (0.56--2.07)                       0.817               
  PCDLBCL‐NOS‐non‐GC                                  53.95         21.58         PCFCCL vs. PCDLBCL‐NOS‐non‐GC                  0.54 (0.25--1.16)                       0.113               
  PCFLBCL‐LT                                          22.69         11.34         PCDLBCL‐NOS‐GC vs. PCDLBCL‐LT                  0.19 (0.09--0.41)                       \<0.001             
                                                                                                                                 PCDLBCL‐NOS‐non‐GC vs. PCDLBCL‐LT       0.38 (0.17--0.88)   0.024
                                                                                                                                 PCDLBCL‐NOS‐GC vs. PCDLBCL‐NOS‐non‐GC   0.50 (0.20--1.23)   0.135
  Analysis of EFS by combined groups                                                                                                                                                         
  PCFCCL+PCDLBCL‐NOS‐GC                               74.27         51.13         \<0.001                                        PCFCCL+PCDLBCL‐NOS‐GC vs. PCDLBCL‐LT    0.20 (0.12--0.35)   \<0.001
  PCDLBCL‐NOS‐non‐GC                                  53.95         21.58         PCDLBCL‐NOS‐non‐GC vs. PCFLBCL‐LT              0.38 (0.17--0.88)                       0.024               
  PCDLBCL‐LT                                          22.69         11.34         PCFCCL+PCDLBCL‐NOS‐GC vs. PCDLBCL‐NOS‐non‐GC   0.53 (0.25--1.12)                       0.098               

OS, overall survival; EFS, event‐free survival; HR, hazard ratio; PCFCCL, primary cutaneous follicular center cell lymphoma; PCDLBCL‐NOS, primary cutaneous diffuse large B‐cell lymphoma, not otherwise specified; PCDLBCL‐LT, primary cutaneous diffuse large B‐cell lymphoma, leg type; PCDLBCL‐NOS‐GC, pCDLBCL‐NOS germinal center B‐cell; PCDLBCL‐NOS‐non‐GC, PCDLBCL‐NOS non‐germinal center B‐cell.
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The combination of PCFCCL and PCDLBCL‐NOS‐GC into a "germinal center" group was tested: this approach identified for PCFCCL+PCDLBCL‐NOS‐GC a significantly different OS as compared to the "high‐grade" subgroup, identified as PCDLBCL‐NOS‐non‐GC+PCDLBCL‐LT (HR 0.05, *P* \< 0.001). Interestingly, statistic significance was retained also toward, respectively, PCDLBCL‐NOS‐non‐GC (HR = 0.10, *P* = 0.005) and PCDLBCL‐LT (HR = 0.03, *P* = 0.001).

Event‐free survival {#cam4865-sec-0013}
-------------------

Event‐free survival (EFS) (Fig. [3](#cam4865-fig-0003){ref-type="fig"}, Table [3](#cam4865-tbl-0003){ref-type="table-wrap"}) was significantly different between the three panel diagnosis (*P* \< 0.001). Post hoc analysis showed a significantly different EFS only for PCFCCL versus PCDLBCL‐LT (HR = 0.21, *P* \< 0.001) and for PCDLBCL‐NOS versus PCDLBCL‐LT (HR = 0.24, *P* \< 0.001).

As to histogenetic subsets, paired comparison resulted in a significantly different EFS only for PCDLBCL‐NOS‐GC versus PCDLBCL‐LT (HR = 0.19, *P* \< 0.001) and for PCDLBCL‐NOS‐non‐GC versus PCDLBCL‐LT (HR = 0.38, *P* = 0.024).

Finally, PCFCCL+PCDLBCL‐NOS‐GC group had a higher EFS when compared to the "high‐grade" group (HR = 0.31, *P* \< 0.001) and to PCDLBCL‐LT (HR = 0.20, *P* \< 0.001), while EFS versus PCDLBCL‐NOS‐non‐GC was still lower but not significant (HR = 0.53, *P* = 0.098).

Survival according to single factors {#cam4865-sec-0014}
------------------------------------

Univariable analysis is detailed in Table [4](#cam4865-tbl-0004){ref-type="table-wrap"}; a further testing was conducted on the group of PCDLBCL (PCDLBCL‐NOS+PCDLBCL‐LT).

###### 

Univariable analysis

  Parameter             All     PCFCCL                PCDLBCL‐NOS   PCDLBCL‐LT   PCDLBCL‐NOS+PCDLBCL‐LT                                                                                                                    
  --------------------- ------- --------------------- ------------- ------------ ------------------------ ------- ------- -------------------- ------- ------- ---------------------- ------- ------- -------------------- -------
  Overall survival                                                                                                                                                                                                         
  Sex                                                                                                                                                                                                                      
  F                     90.08   ---                   0.381                                                                                                                                                                
  M                     88.14   1.60 (0.56--4.54)                                                                                                                                                                          
  Age                                                                                                                                                                                                                      
  \<70 years            95.98   ---                   0.003                                                                                                                                                                
  \>70 years            80.94   9.51 (2.17--41.62)                                                                                                                                                                         
  Histogenesis                                                                                                                                                                                                             
  GC                    94.12   ---                   \<0.001                                                                                                                                                              
  Non‐GC                69.59   0.07 (0.03--0.21)                                                                                                                                                                          
  Bcl2 IHC                                                                                                                                                                                                                 
  −                     94.58   ---                   0.001         96.88        ---                      0.348   95.00   ---                  0.242   66.67   ---                    0.628   88.67   ---                  0.043
  \+                    77.74   5.74 (1.99--16.57)                  90.91        3.77 (0.24--60.37)               92.31   3.43 (0.44--27.00)           53.03   0.67 (0.14--3.31)              69.73   3.40 (1.04--11.09)   
  DHS                                                                                                                                                                                                                      
  0--1                  94.59   ---                   \<0.001       NA           NA                       NA      92.86   ---                  0.919   80.00   ---                    0.322   89.64   ---                  0.053
  2                     53.59   13.15 (4.37--39.63)                                                               83.33   1.12 (0.12--10.98)           36.46   2.89 (0.35--23.50)             53.59   3.43 (0.98--11.95)   
  Bcl2 translocation                                                                                                                                                                                                       
  Absent                91.66   ---                   0.502         100          ---                      0.020   94.12   NA                   NA      NA      NA                     NA      80.52   ---                  0.594
  Present               75.56   1.71 (0.36--8.13)                   80.00        19.24 (3.21--115.44)             100                                                                         75.00   1.77 (0.22--14.49)   
  Number of lesions                                                                                                                                                                                                        
  Single                88.67   ---                   0.895         93.48        ---                      1.000   95.24   ---                  0.512   59.89   ---                    0.557   82.23   ---                  0.494
  Multiple              89.21   1.07 (0.40--2.90)                   100          0.00 (0.00)                      90.91   1.93 (0.27--13.83)           42.86   1.47 (0.41--5.27)              72.69   1.44 (0.51--4.04)    
  Leg                                                                                                                                                                                                                      
  No                    94.48   ---                   \<0.001       97.56        ---                      0.037   92.57   ---                  0.554   60.00   ---                    0.620   87.23   ---                  0.013
  Yes                   68.34   9.64 (3.52--26.40)                  66.67        19.21 (1.20--307.56)             100     2.01 (0.20--20.07)           51.81   1.49 (0.31--7.11)              67.58   3.97 (1.33--11.81)   
  Anatomic site                                                                                                                                                                                                            
  Lower limbs           68.34   ---                   ---           66.67        ---                      ---     100     ---                  ---     51.81   ---                    ---     67.58   ---                  ---
  Upper limbs           92.86   0.19 (0.02--1.49)     0.114         100          0.00 (0.00)              1.000   100     0.00 (0.00)          1.000   0.00    4.63 (0.51--41.68)     0.172   87.50   0.27 (0.03--2.11)    0.211
  Trunk                 95.13   0.11 (0.03--0.38)     0.001         95.00        0.11 (0.01--1.72)        0.115   93.75   0.58 (0.05--6.61)    0.658   100     0.00 (0.00)            1.000   94.74   0.17 (0.04--0.80)    0.025
  Head/neck             97.30   0.04 (0.01--0.31)     0.002         100          0.00 (0.00)              1.000   85.71   0.70 (0.04--11.45)   0.803   NA      NA                     NA      85.71   0.23 (0.03--1.82)    0.163
  Event‐free survival                                                                                                                                                                                                      
  Sex                                                                                                                                                                                                                      
  F                     53.56   ---                   0.044                                                                                                                                                                
  M                     35.39   1.63 (1.01--2.62)                                                                                                                                                                          
  Age                                                                                                                                                                                                                      
  \<70 years            47.64   ---                   0.167                                                                                                                                                                
  \>70 years            36.69   1.37 (0.88--2.13)                                                                                                                                                                          
  Histogenesis                                                                                                                                                                                                             
  GC                    49.61   ---                   \<0.001                                                                                                                                                              
  Non‐GC                12.65   0.32 (0.19--0.53)                                                                                                                                                                          
  Bcl2 IHC                                                                                                                                                                                                                 
  −                     45.60   ---                   0.177         51.33        ---                      0.836   36.32   ---                  0.531   0.00    ---                    0.083   31.68   ---                  0.602
  \+                    35.49   1.37 (0.87--2.18)                   47.37        1.08 (0.51--2.29)                49.23   0.73 (0.28--1.93)            12.96   0.32 (0.09--1.16)              28.34   1.19 (0.62--2.26)    
  DHS                                                                                                                                                                                                                      
  0--1                  45.07   ---                   0.011         NA           NA                       NA      28.57   ---                  0.741   30.00   ---                    0.454   22.71   ---                  0.334
  2                     28.42   2.20 (1.19--4.06)                                                                 57.14   0.80 (0.22--2.97)            11.00   0.63 (0.19--2.10)              28.42   1.46 (0.68--3.18)    
  Bcl2 translocation                                                                                                                                                                                                       
  Absent                42.57   ---                   0.324         50.39        ---                      0.210   47.44   ---                  0.677   13.40   ---                    0.037   31.55   ---                  0.773
  Present               26.23   1.41 (0.71--2.79)                   29.09        1.72 (0.74--4.02)                33.33   1.39 (0.30--6.49)            0.00    19.00 (1.19--303.76)           25.00   1.19 (0.36--3.98)    
  Number of lesions                                                                                                                                                                                                        
  Single                43.16   ---                   0.756         53.06        ---                      0.637   41.49   ---                  0.830   8.99    ---                    0.487   28.98   ---                  0.990
  Multiple              39.94   1.08 (0.67--1.72)                   48.64        1.17 (0.61--2.21)                27.20   0.90 (0.34--2.37)            14.29   1.42 (0.53--3.76)              20.20   1.00 (0.50--1.98)    
  Leg                                                                                                                                                                                                                      
  No                    49.40   ---                   \<0.001       22.22        ---                      0.113   24.31   ---                  0.432   20.00   ---                    0.465   40.05   ---                  0.005
  Yes                   14.83   3.18 (1.91--5.28)                   53.61        2.32 (0.82--6.59)                43.87   1.57 (0.51--4.83)            8.04    1.53 (0.49--4.81)              13.13   2.63 (1.34.5.15)     
  Anatomic site                                                                                                                                                                                                            
  Lower limbs           14.82   ---                   ---           22.22        ---                      ---     24.31   ---                  ---     8.04    ---                    ---     13.13   ---                  ---
  Upper limbs           24.19   0.64 (0.39--1.37)     0.248         0.00         1.20 (0.29--4.86)        0.802   35.71   1.14 (0.30--4.42)    0.846   0.00    2.26 (0.28--18.15)     0.444   31.25   0.67 (0.26--1.76)    0.418
  Trunk                 51.97   0.33 (0.18--0.57)     \<0.001       53.58        0.57 (0.19--1.70)        0.315   53.72   0.50 (0.14--1.74)    0.276   33.33   0.40 (0.08--1.91)      0.252   50.18   0.29 (0.13--0.66)    0.003
  Head/neck             55.97   0.22 (0.11--0.41)     \<0.001       61.24        0.27 (0.09--0.84)        0.023   26.79   0.61 (0.15--2.49)    0.493   NA      NA                     NA      26.79   0.31 (0.10--0.94)    0.039

HR, hazard ratio; PCFCCL, primary cutaneous follicular center cell lymphoma; PCDLBCL‐NOS, primary cutaneous diffuse large B‐cell lymphoma, not otherwise specified; PCDLBCL‐LT, primary cutaneous diffuse large B‐cell lymphoma, leg type; GC germinal center B‐cell; non‐GC, non‐germinal center B‐cell; IHC, immunohistochemistry; DHS, double‐hit score; NA, not assessed (group too small for statistical analysis).
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As to immunophenotypic features, on the complete series, a GC histogenetic profile distinguishes a whole group both with a better OS (HR = 0.07, *P* \< 0.001) and EFS (HR = 0.32, *P* \< 0.001); this observation was true also excluding PCDLBCL‐LT cases from the analysis. BCL2 positivity negatively impacted OS but not EFS on the whole series. According to the panel diagnosis, there was a trend toward ad increase in OS, though above the threshold of significance while an inverse tendency, though still not significant, was observed for EFS. OS was significantly impacted when considering only cases with a large cell histology (HR = 3.43, *P* = 0.043). DHS proved to impact OS (*P* \< 0.001) and EFS (*P* = 0.011) on the whole series and to be helpful in identifying a subset of cases with a lower survival in the large cell subgroup (HR = 3.43, *P* = 0.05).

Although based on few events, the presence of *BCL2* translocation proved to impact significantly OS in PCFCCL, whereas for EFS, it was significant only for PCDLBCL‐LT.

Age at diagnosis \>70 years correlated with a significantly lower OS (HR = 9.51, *P* = 0.003). Male sex resulted to be a factor of risk, although statistically significant only for EFS.

Lesional pattern (single vs. multiple lesions) did not show any significant impact. Localization on the lower limbs correlated with worse OS and EFS on the whole series, whereas according to the panel diagnosis, it was significant only for PCFCCL, however based on a single event. A significance was observed also in the large cell subgroup, with a lower OS and HR = 3.97 (*P* = 0.013) for leg site, whereas the highest OS was related to localization on the trunk.

Discussion {#cam4865-sec-0015}
==========

The controversies in PCBCL classification primarily reflect the rarity and clinical heterogeneity of the disease. From the histopathologist\'s standpoint, the major challenge is the proper classification of PCBCL displaying a diffuse pattern and a predominant large cell histology.

We defined PCDLBCL‐NOS as a subset of cases exhibiting diffuse large B‐cell histology, not fitting into PCFCCL diffuse type subgroup nor in PCDLBCL‐LT both in cytology and in phenotype. PCDLBCL‐NOS predominantly consisted of centroblasts, often intermingled with a brisk infiltrate of small lymphocytes, which are usually inconspicuous in PCDLBCL‐LT. However, PCDLBCL‐NOS differed from PCFCCL because large centrocytoid cells represented only a limited fraction (\<10%) of the infiltrate, whereas no dendritic meshwork was detectable other than minimal remnants (in a minority of cases). Phenotypically, they variably expressed MYC and BCL2 that were intensely coexpressed in PCDLBCL‐LT. PCDLBCL‐NOS partially overlapped with the subset of PCDLBCL‐other as described in the 2005 WHO/EORTC classification [7](#cam4865-bib-0007){ref-type="ref"}, [8](#cam4865-bib-0008){ref-type="ref"} and by Kodama et al. [14](#cam4865-bib-0014){ref-type="ref"}, where they are reported to have histologic features in between PCFCCL and PCDLBCL‐LT, showing predominance of round cells and variable BCL2 expression.

We aimed to clarify whether PCDLBCL‐NOS represents a distinct clinicopathologic subset or simply a morphophenotypic variant of PCFCCL and/or PCDLBCL‐LT by analyzing their outcome. Comparison of PCDLBCL‐NOS as a whole with PCFCCL resulted in a difference in OS, though below the threshold of significance. Separation of PCDLBCL‐NOS upon histogenetic profile documented a worse prognosis for the non‐GC subgroup, whereas cases with a GC profile were more similar to PCFCCL. Since PCDLBCL‐NOS with a GC profile cannot be distinguished from the more aggressive PCDLBCL‐NOS with a non‐GC profile on the sole morphological ground, we think that a more accurate prognostic stratification of this category should rely on the immunophenotypic and/or molecular characterization. As well, cases of PCDLBCL‐NOS with a non‐GC profile would be classified by some pathologists as PCFCCL [15](#cam4865-bib-0015){ref-type="ref"} with high content of blast cells, but they are different in terms of both clinical course and outcome (shorter survival) as compared to PCFCCL. Although the small number of cases of PCDLBCL‐NOS with a non‐GC phenotype did not allow us to reach a statistical significance when comparing their outcome to PCDLBCL‐LT, a trend toward a less aggressive course was observed. Notably, PCDLBCL‐NOS‐non‐GC clearly differs from PCDLBCL‐LT in terms of presentation site, cytologic features (centroblasts with an intermixed reactive infiltrate), and phenotype (rare MYC/BCL2 coexpression).

Since the description of PCDLBCL‐LT by Vermeer et al. [16](#cam4865-bib-0016){ref-type="ref"}, the concept of PCDLBCL has been tightly connected to a specific anatomic location on the lower limbs, as well as the "leg" involvement denoted a poor prognostic indicator. Further series reported an analogous behavior for PCDLBCL‐LT arising at different sites [3](#cam4865-bib-0003){ref-type="ref"}. Our study highlights that the prognostic role of the leg location is retained on the whole series but not in PCDLBCL‐LT alone, which in turn arises more frequently in the lower extremities. This finding suggests that histopathology and other biologic factors rather than "leg" location only might be predictive of a potential aggressive behavior.

First‐line treatment was mainly radiotherapy in PCFCCL (49%) and chemotherapy (±local radiotherapy) in both PCDLBCL‐LT (60%) and PCDLBCL‐NOS (55%). However, follow‐up data of PCDLBCL‐NOS were more similar to PCFCCL and complete response and relapse rate and number of patients alive free of disease consistently differed from PCDLBCL‐LT (Table [2](#cam4865-tbl-0002){ref-type="table-wrap"}). With the limitations of a retrospective data collection, these observations suggest the opportunity of a radiotherapy‐privileged first‐line treatment for PCDLBCL‐NOS, particularly in cases with a GC profile.

PCFCCL and PCDLBCL‐LT harbor different molecular profiles [4](#cam4865-bib-0004){ref-type="ref"}, [5](#cam4865-bib-0005){ref-type="ref"}, [6](#cam4865-bib-0006){ref-type="ref"}, [17](#cam4865-bib-0017){ref-type="ref"}, [18](#cam4865-bib-0018){ref-type="ref"}; however, only limited data are available on the above‐mentioned subset with features in between PCFCCL and PCDLBCL‐LT [19](#cam4865-bib-0019){ref-type="ref"}. We applied Hans algorithm, as a surrogate of gene expression profiling (GEP) to define the histogenesis, and DHS to test the prognostic impact of two immunohistochemical algorithms validated in the diagnostic workup of systemic DLBCL [12](#cam4865-bib-0012){ref-type="ref"}, [13](#cam4865-bib-0013){ref-type="ref"}. We are well aware that immunohistochemical algorithms remain an imperfect substitution of GEP, partly due to their inherent oversimplification; nonetheless they provide a practical way of designating subtype and may be sufficient for the purpose of achieving population enrichment on clinical trials, although being less reliable for individual patient management [20](#cam4865-bib-0020){ref-type="ref"}. However, our results seem to enhance the concept of cell‐of‐origin and its prognostic relevance also in the setting of PCBCL, since we distinguished PCDLBCL‐NOS with a non‐GC phenotype as having an intermediate behavior between classic PCFCCL and PCDLBCL‐LT. As to DHS, though basing on a limited number of cases, BCL2/MYC coexpression proved helpful to identify cases with a more aggressive course among the whole group of PCDLBCLs, in a way independent from the histology. The latter observation was confirmed also for the sole BCL2 positivity. However, the definition of the genetic landscape of PCDLBCL‐NOS in comparison with PCDLBCL‐LT and PCFCCL could be a matter of future interest.

Currently no widely accepted prognostic indicators exist for PCFCCL. Similarly to previous reports, our series of PCFCCL showed an excellent prognosis with a 5‐year disease‐specific survival over 95% and only two patients dead of progression to systemic lymphoma. In our series, leg presentation and presence of t(14;18)(q32;q21) adversely affected prognosis. Whereas the former has been already associated with a more aggressive course [3](#cam4865-bib-0003){ref-type="ref"}, the prognostic role of t(14:18) is still debated.

t(14;18)(q32;q21) involves *BCL2* and *IGH* and represents the cytogenetic hallmark of nodal follicular lymphoma, whereas its detection in PCFCCL requires to exclude a secondary localization [21](#cam4865-bib-0021){ref-type="ref"}. *BCL2* translocation has been variably detected in PCFCCL both in studies using polymerase chain reaction (PCR)‐based methods (0--34%) and FISH analysis (0--41%) (Table [5](#cam4865-tbl-0005){ref-type="table-wrap"}) [21](#cam4865-bib-0021){ref-type="ref"}, [22](#cam4865-bib-0022){ref-type="ref"}, [23](#cam4865-bib-0023){ref-type="ref"}, [24](#cam4865-bib-0024){ref-type="ref"}, [25](#cam4865-bib-0025){ref-type="ref"}, [26](#cam4865-bib-0026){ref-type="ref"}, [27](#cam4865-bib-0027){ref-type="ref"}, [28](#cam4865-bib-0028){ref-type="ref"}, [29](#cam4865-bib-0029){ref-type="ref"}, [30](#cam4865-bib-0030){ref-type="ref"}, [31](#cam4865-bib-0031){ref-type="ref"}, [32](#cam4865-bib-0032){ref-type="ref"}, [33](#cam4865-bib-0033){ref-type="ref"}. Possible explanations for this wide range include geographic distribution, the limited number and heterogeneity of at least some of the reported series, and variation in the diagnostic criteria in different studies, probably including cases of skin involvement in the course of systemic follicular lymphoma. The clinical relevance of *BCL2* rearrangement in PCFCCL is controversial. Abdul‐Wahab et al. [32](#cam4865-bib-0032){ref-type="ref"} reported that chromosomal anomalies, including t(14;18), do not portend a poor prognosis, as *BCL2*‐translocated patients do not differ in terms of clinical outcome and invariably respond to radiotherapy. On the contrary, Pharm Ledard et al. [33](#cam4865-bib-0033){ref-type="ref"} reported that *BCL2* rearrangement correlates to a higher risk of extracutaneous spread.

###### 

Comparison of BCL2 evaluation in PCFCCL among series

  Evaluation of BCL2                                                   IHC           PCR           FISH
  -------------------------------------------------------------------- ------------- ------------- -------------
  Cerroni et al., 2000 [22](#cam4865-bib-0022){ref-type="ref"}         0/15          0/15          NA
  Franco et al., 2001 [21](#cam4865-bib-0021){ref-type="ref"}          11/18 (61%)   0/18          NA
  Bergman et al., 2001 [23](#cam4865-bib-0023){ref-type="ref"}         4/19 (21%)    2/15 (13%)    NA
  Aguilera et al., 2001 [24](#cam4865-bib-0024){ref-type="ref"}        11/18 (61%)   3/17 (18%)    NA
  Child et al., 2001 [25](#cam4865-bib-0025){ref-type="ref"}           0/25          0/25          NA
  Lawnicki et al., 2002 [26](#cam4865-bib-0026){ref-type="ref"}        8/20 (40%)    4/20 (20%)    NA
  Goodlad et al. 2002 [27](#cam4865-bib-0027){ref-type="ref"}          3/16 (81%)    0/16          NA
  Mirza et al., 2002 [28](#cam4865-bib-0028){ref-type="ref"}           13/32 (41%)   11/32 (34%)   NA
  Vergier et al., 2004 [29](#cam4865-bib-0029){ref-type="ref"}         17/30 (57%)   9/30 (30%)    0/17
  Kim et al., 2005 [30](#cam4865-bib-0030){ref-type="ref"}             17/30 (57%)   NA            4/13 (31%)
  Streubel et al., 2006 [31](#cam4865-bib-0031){ref-type="ref"}        10/27 (37%)   0/17          11/27 (41%)
  Abdul‐Wahab et al., 2014 \[[32](#cam4865-bib-0032){ref-type="ref"}   6/57 (11%)    NA            4/49 (8%)
  Pharm Ledard et al., 2015 [33](#cam4865-bib-0033){ref-type="ref"}    25/47 (53%)   NA            4/47 (8.5%)
  Present series                                                       29/96 (30%)   NA            15/75 (20%)

BCL2, B‐cell lymphoma; PCFCCL, primary cutaneous follicular center cell lymphoma; IHC, immunohistochemistry; PCR, polymerase chain reaction; FISH, fluorescence in situ hybridization; NA, not assessed.
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To the best of our knowledge, the present series is the largest ever tested for *BCL2* rearrangement, encompassing the entire histologic spectrum of PCFCCL according to the WHO classification. FISH was preferred, due to its higher sensitivity for detection of *IGH/BCL2* rearrangement than PCR [31](#cam4865-bib-0031){ref-type="ref"}. We documented t(14;18)(q32;q21) in 15/75 (18%) patients, of which seven patients experienced cutaneous relapses and one patient died after systemic progression. Discordance between the presence of *BCL2* translocation and protein expression is a well‐reported occurrence in a limited fraction of systemic FL, which may lie with mutational events at *BCL2* locus [34](#cam4865-bib-0034){ref-type="ref"}. We tested our cases using BCL2 clone 124, and a significant correlation was found between protein expression and t(14;18), since it occurred in 48% BCL2‐positive cases but only in 8% BCL2‐negative cases (*P* \< 0.001). While the presence of t(14;18) was associated with decreased OS, BCL2 expression did not seem to affect prognosis: as a consequence, FISH analysis could be included in the PCFCCL work‐up, to identify patients requiring closer monitoring.

Our findings indicate that PCLBCL includes different subsets, among which the so‐called leg type probably represents an aggressive clinical variant; a further group may exist, exhibiting clinicopathologic features intermediate between PCFCCL and PCDLBCL‐LT. Careful combination of morphological and immunophenotypic criteria with adequate clinical information is crucial to identify such cases.
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###### 

**Figure S1.** The typical picture of PCFCCL displays a nodular (A, hematoxylin--eosin 20×) to diffuse proliferation composed of small‐ to medium‐sized centroblasts (B, hematoxylin--eosin 400×), with a variable proportion of centroblast or with a spindle cell morphology (C, hematoxylin--eosin 200×). BCL2 is usually negative (D, SABC method, 400×) and CD10 is positive (E, SABC method, 200×), whereas a residual, CD23+ positive dendritic meshwork is typically present (F, SABC method, 200×).

###### 

Click here for additional data file.

###### 

**Figure S2.** A representative picture of the presence of t(14;18) is depicted (A, *IGH/BCL2* Dual Color, Dual Fusion Translocation Probe, 1000×). EBV status was invariably negative (B, EBER‐ISH, 400×); slides taken from nonkeratinizing undifferentiated nasopharyngeal carcinoma were used as positive control (B, inset).

###### 

Click here for additional data file.
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